- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05360433
Too Much of a Good Thing? Impact of Initial Prescription Size in Post-cesarean Section Pain Management
Impact of Reduced Initial Prescription Size on Opioid Consumption in Postoperative Pain Management for Scheduled Cesarean Deliveries
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
All faculty scheduled cesarean deliveries will be eligible for possible enrollment. Once patients are scheduled for delivery, their providers will grant permission for potential participation in the study. Two weeks prior to surgery, potential participants will receive a phone call to assess interest and eligibility for participation. During the phone call, investigators will explain the goals of this research project and the overall study design. If an individual expresses interest in participation during this initial phone call, investigators will administer an intake survey. The intake survey is designed to collect data on participant eligibility as well as preexisting attitudes and experiences that may influence postoperative opioid consumption.
Patients who complete the initial survey will be approached by a member of the research team on postoperative day two or three prior to discharge from the hospital. At this time, investigators will obtain informed consent and provide each participant with an enrollment packet prepared by the principal investigator. The enrollment packet will contain educational components including information about opioids with specific instructions about how to use opioids for pain management and instructions on proper disposal of unused tablets. Investigators will also include information about alternative forms of analgesia (ibuprofen and acetaminophen) with FDA approved instructions regarding their use in pain management. The study team's goal in including these educational components for each study group is to ensure that women are able to make safe and informed decisions regarding both forms of medication for optimal pain management. The enrollment packet will also include copies of all surveys the participants will be completing and a visual representation of the numerical pain scale for participants to reference.
Women in the study will be randomized to receive either 10 or 20 tablets of oxycodone 5 mg upon discharge. Randomization of prescription groups will be achieved using a computer randomized sequence assigning participants in a 1:1 ratio to either a standard discharge prescription size (20 tablets oxycodone 5mg) or a reduced initial prescription size (10 tablets oxycodone 5 mg). Participants will not be given information regarding prescription size of other participants in the study, and will therefore be blinded as to whether or not their prescription size represents the larger or smaller group.In the event that a participant should require more opioid tablets for pain medication, there will be an option to request a refill from a designated provider. Refills across both groups will be standardized to a size of 5 tablets and healthcare providers will be notified of the participant's request in order to help determine if an earlier postoperative visit is needed for evaluation.
Outcome metrics will be collected at 3 different postoperative time points. The initial "inpatient survey" will be completed in person at the time of consent on postoperative day two or three. This survey is designed to collect information about each participant's perceived pain experience during inpatient stay and capture pain rating at time of discharge. Outcome metrics at two subsequent time points (10-14 days post-op and 6 weeks post-op) will be collected using an "outpatient survey." Participants will be given the option to complete the outpatient surveys over the phone with the investigator directly inputting metrics or through an online survey directly linked to the study electronic database. Follow-up surveys will assess a number of outcome metrics related to opioid use, participant's pain experience, and participant satisfaction with pain management.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Robyn N Goodrich, BA
- Numéro de téléphone: 434-825-7630
- E-mail: rgoodrich@vt.edu
Sauvegarde des contacts de l'étude
- Nom: Jaclyn D Nunziato, MD
- Numéro de téléphone: 540-655-0459
- E-mail: jdnunziato@carilionclinic.org
Lieux d'étude
-
-
Virginia
-
Roanoke, Virginia, États-Unis, 24014
- Recrutement
- Carilion Roanoke Memorial Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Female
- Age 19-40 years old
- Pregnant
- Scheduled to undergo cesarean section at Carilion Roanoke Memorial Hospital
- opioid naïve (defined as no opioid use within 30 days of surgery
Exclusion Criteria:
- History of chronic pain
- History of opioid use disorder
- History of any known intolerance or allergies to analgesics
- Women with postoperative complications (hysterectomy during or after birth, bowel or bladder injury during birth, need for re-operation, or immediate wound complication)
- Language barrier preventing screening or consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 10 tablet prescription group
These participants receive 10 tablets of oxycodone 5 mg at discharge for postoperative pain.
|
Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
Autres noms:
|
|
Comparateur actif: 20 tablet prescription group
These participants receive 20 tablets of oxycodone 5 mg at discharge for postoperative pain.
|
Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total opioid consumption by participants post-cesarean delivery
Délai: 2 weeks
|
Number of tablets of oxycodone consumed for postoperative pain management.
This will be measured by a pill count at the participant's 2 week post-op visit and the participant's responses to postoperative surveys at 2 weeks and 6 weeks post surgery.
|
2 weeks
|
|
Total opioid consumption by participants post-cesarean delivery
Délai: 6 weeks
|
Number of tablets of oxycodone consumed for postoperative pain management.
This will be measured by a pill count at the participant's 2 week post-op visit and the participant's responses to postoperative surveys at 2 weeks and 6 weeks post surgery.
|
6 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Participant pain rating
Délai: 2 weeks
|
reported level pain based on Numeric Pain Rating Scale (NPRS) 0-10, with 0 being no pain and 10 being the worst pain imaginable
|
2 weeks
|
|
Participant pain rating
Délai: 6 weeks
|
reported level pain based on Numeric Pain Rating Scale (NPRS) 0-10, with 0 being no pain and 10 being the worst pain imaginable
|
6 weeks
|
|
Participant satisfaction with pain management
Délai: 2 weeks
|
Patient reported satisfaction with postoperative pain management on survey based on opinion of whether medications provided were strong enough and the quantity of medication provided Participants are asked "were you overall satisfied with your pain management since surgery" and answer yes or no
|
2 weeks
|
|
Participant satisfaction with pain management
Délai: 6 weeks
|
Patient reported satisfaction with postoperative pain management on survey based on opinion of whether medications provided were strong enough and the quantity of medication provided Participants are asked "were you overall satisfied with your pain management since surgery" and answer yes or no
|
6 weeks
|
|
Requests for opioid prescription refills by participants
Délai: 2 weeks
|
Number of opioid refills required by participant requesting additional medication up to 6 weeks post operative
|
2 weeks
|
|
Requests for opioid prescription refills by participants
Délai: 6 weeks
|
Number of opioid refills required by participant requesting additional medication up to 6 weeks post operative
|
6 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jaclyn D Nunziato, MD, Carilion Clinic
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Complications postopératoires
- La douleur
- Manifestations neurologiques
- Douleur, Postopératoire
- Effets physiologiques des médicaments
- Dépresseurs du système nerveux central
- Agents du système nerveux périphérique
- Analgésiques
- Agents du système sensoriel
- Analgésiques, Opioïdes
- Stupéfiants
- Oxycodone
Autres numéros d'identification d'étude
- 19-516
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .